STUDresearch · Non-peptide
SR9009
Also known as
Stenabolic · SR-9009 · SR 9009 · REV-ERB agonist SR9009 · Rev-ErbA agonist SR9009 · Scripps REV-ERB ligand SR9009
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral; animal IP
Metabolic research compounds
Systemic — experimental REV-ERB ligand studied in whole-body circadian, metabolic and skeletal-muscle programs; not a peptide.
What people say
SR9009 is an experimental small-molecule ligand developed as a REV-ERB alpha/beta agonist, not a SARM or peptide. Metabolic, circadian and endurance evidence is preclinical, and later cell work found important REV-ERB-independent effects.
Doses people talk about
Rows keep route, frequency and evidence class explicit. Community bands are not an escalation ladder, and animal mg/kg cannot be converted into an oral human regimen from these data.
How it may feel
Inspected reports range from no noticeable effect to immediate warmth, energy and higher heart rate. Sleep reports also conflict: one heavily confounded split-dose account reported strong sleep, while another liquid user reported reduced deep sleep. No reliable onset, duration or prevalence follows from these posts.
Inspected stacked report10 mg oral three times daily
One author reported dosing about every four hours for 1.5 months with weekends off while also using 10 mg/day GW-501516 and maintaining heavy work and training; attribution and product identity remain unresolved.
Common guide range20–30 mg oral daily
The preserved profile identifies this as a modal vendor/forum band, not a measured human protocol.
Lower guide range10–15 mg oral daily
A separate unvalidated community band, sometimes described with even lower total amounts while testing product response or sleep.
Upper guide range30–40 mg oral daily
Unvalidated community performance language; some charts extend toward 50 mg/day without a human maximum-tolerated-dose study.
Mouse metabolic studies100 mg/kg IP twice daily
A high-dose intraperitoneal mouse regimen used in preclinical studies; not an oral human recipe.
Half-life & effect duration
- Half-life in the body
- Community estimateAbout 4 hours
- Animal-study summariesAbout 2 hours
- Felt duration people report
- One liquid-product accountImmediate energy, warmth and heart-rate change, with poorer deep sleep
- Other accountsNo effect, or good sleep within a Cardarine stack
Cycles people discuss
Community discussion commonly frames four-to-ten-week blocks and varied time off, often in multi-compound cutting stacks. Those calendars are not pharmacology-derived human protocols, and published animal regimens do not validate them.
Timing
Community charts spread oral use across two to four daily administrations. One inspected author used three daily doses about four hours apart, including at night; these are self-experiment schedules, not human-PK-derived intervals or a controlled sleep cutoff.
Stacks
Cardarine, stimulants and other cutting agents frequently appear beside SR9009, but they confound energy, heart-rate, sleep and body-composition reports. SR9011 and SLU-PP compounds are comparisons from different evidence contexts, not dose-equivalent combinations.
Watch for
No human safety package: Oral fitness use lacks adequate Phase 1 PK, MTD, or long-term controlled safety databases; absence of reports ≠ proof of safety.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A numerical human oral parent-plasma half-life for SR9009 was not established by the reviewed sources.
The primary program located here consists of cell and mouse work, including high-dose intraperitoneal regimens; forum users repeat roughly four-hour estimates without a clinical PK table.
Mouse route and exposure, dosing intervals, vendor summaries and subjective windows cannot establish human oral absorption, bioavailability, half-life or redosing.
- Solt et al. — Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists (opens in a new tab)Primary discovery paper characterizes SR9009 and SR9011 in cell assays and mice, including 100 mg/kg intraperitoneal SR9009 twice daily for six days; it does not provide human oral PK.Cell and mouse research using intraperitoneal exposure; it cannot establish human oral dosing, bioavailability, safety or half-life.
- Dierickx et al. — SR9009 has REV-ERB-independent effects on cell proliferation and metabolism (opens in a new tab)Primary cell study found effects on proliferation, mitochondrial respiration and gene expression in REV-ERB alpha/beta double-knockout systems, showing substantial effects cannot be assigned solely to REV-ERBs.In-vitro mouse and human cell systems at experimental concentrations; no human PK, clinical efficacy or consumer-product verification.
- Reddit r/sarmssourcetalk — Any experiences with SR9009 regarding sleep? (opens in a new tab)Multiple authors reported no effect, strong sleep during 10 mg three-times-daily use with GW-501516 and heavy workload, or immediate energy, warmth, higher heart rate and poorer deep sleep from a liquid product.Anonymous multi-author discussion with unverified products, incomplete dose reporting and major stack, schedule, training and workload confounding.
Felt duration people report
The inspected discussion does not establish a consistent onset or duration for energy, warmth, heart-rate or sleep effects.
One user reported no effect, a liquid user reported an immediate energy, warmth and heart-rate change with poorer deep sleep, and a split-dose user in a GW-501516 stack reported sleeping well.
Anonymous reports used unverified products and incompletely reported doses, with major stack, workload, training, sleep-history and selection confounding.
- Reddit r/sarmssourcetalk — Any experiences with SR9009 regarding sleep? (opens in a new tab)Multiple authors reported no effect, strong sleep during 10 mg three-times-daily use with GW-501516 and heavy workload, or immediate energy, warmth, higher heart rate and poorer deep sleep from a liquid product.Anonymous multi-author discussion with unverified products, incomplete dose reporting and major stack, schedule, training and workload confounding.
What people say
- Lean / “exercise mimetic” media frame: Burris-era quotes (“muscles like an athlete who has been training”) drove forum branding; animal sedentary-mouse treadmill gains do not prove human oral recomp. animalforum
- User endurance logs: Subjective better steady-state cardio, delayed fatigue, or easier Zone-2 / high-volume sessions — heavily confounded by training, deficit, caffeine, and Cardarine co-use. forumanecdote
- Cut / recomp logs: Claim easier fat loss or “harder look” on a cut; almost always stacked (GW, mild SARMs, stims) so attribution is weak. forum
- Energy without classic stim buzz: Some report “cleaner” drive or readiness without jitter; others report nothing or early lethargy — inconsistent. anecdote
- Non-androgenic appeal: Community markets “no testosterone suppression / no PCT” vs true SARMs or AAS — mechanism supports no AR binding, but product purity and unstudied REV-ERB/Leydig interactions keep that claim soft. forumtrial
- Evidence honesty: Mouse metabolic + endurance package is the real signal; human oral efficacy at 20–40 mg/day retail is unproven and may be limited by absorption. trialforum
- Mitochondria / oxidative muscle (preclinical): Higher mitochondrial content and function markers in muscle after REV-ERB activation in mouse and culture work — origin of “cardio conditioning without training” hype. animal
- Lipids and body mass (Solt / Nature 2012 line): Diet-induced obese mice given high-dose IP SR9009 (commonly described as 100 mg/kg IP, often BID in methods write-ups) lost weight/fat mass vs vehicle and showed lower triglycerides, cholesterol, free fatty acids, and improved fasting glucose / insulin-sensitivity signals over multi-day to multi-week windows. Secondary summaries sometimes quote large TG/FFA percent drops — always animal IP, not oral human. animal
- Vs Cardarine (community framing): SR9009 cast as resting metabolic / mitochondrial / clock-adjacent; GW as training-session fat oxidation + longer half-life endurance. No head-to-head human trial. forum
- Mouse endurance (Woldt / Nature Medicine 2013 line): Pharmacologic REV-ERBα activation with SR9009 increased treadmill running time and distance vs vehicle; popular summaries and Scripps/media pieces cite roughly ~50% higher running capacity (time and distance) in treated mice, with mitochondrial biogenesis / oxidative-capacity framing in skeletal muscle. animal
Doses people talk about
- Most common daily total: ~20–30 mg/day oral is the modal band across SARM-shop guides and forum protocols. forum
- Lower / first-run band: ~10–15 mg/day (or conservative starts near ~5–10 mg total) when testing sleep tolerance or product response. forum
- Upper community band: ~30–40 mg/day often called a performance or “full” range; some charts stretch toward ~50 mg/day — still unvalidated human MTD. forum
- Broad chart range: Secondary “bodybuilding guides” often print ~5–50 mg/day as the full discussed span, with 20–30 mg as the center of mass. forum
- Split dosing (core practice): Short duration → almost always 2–4 oral administrations per day rather than once daily. Once-daily is widely called the main rookie mistake. forum
- Per-dose math (examples discussed): 20 mg total → e.g. 10+10 or ~7+7+6; 30 mg total → 10 mg × 3 or 7.5 mg × 4; 40 mg total → 10 mg × 4. Exact splits vary by lifestyle. forum
- Frequency table culture: Conservative 2×/day; “standard” 3×/day for more stable levels; performance-focused 4×/day especially in final cut weeks. forum
- Pre-workout anchor: Many keep one dose ~30–45 minutes before cardio or high-volume training on top of the split schedule. forum
- Half-life-driven schedule math: Forums cite ~4 hour (sometimes 2–6 hour) half-life → dose every ~4–6 hours while awake; late-night doses often skipped for sleep. forumanimal
- Animal → human math caution: Oral charts reverse-engineered from IP rodent mg/kg with arbitrary bioavailability fudge factors have no clinical validation; poor oral F is the main scientific objection. forumtrial
- Sublingual / cyclodextrin marketing: Vendors claim better absorption vs plain oral; peer-reviewed human F for those formulations is not established. forum
- Framing: All human-facing figures below are community research-chem discussion, vendor charts, or reverse-engineered guesses from animal PK — not clinical protocols, not medical advice, not consumption guidance. forum
- Animal study doses (context only): Solt-line DIO work commonly 100 mg/kg IP, often BID (e.g. CT0 and CT12) for days to ~30 days; cardiac/other models use high IP mg/kg once daily; some exploratory work uses lower IP (e.g. ~10–50 mg/kg) depending on endpoint. These are not oral human recipes. animal
How it may feel
- Inspected immediate reports conflict: One oral user reported no effect, while a liquid user described a rapid energy surge, warmth and higher heart rate. Product identity and dose were unverified, so these accounts do not establish a typical onset or stimulant profile. forumanecdote
- Sleep reports conflict: One author using 10 mg three times daily with GW-501516, heavy work and training said sleep remained strong; another liquid user reported poorer deep sleep. The stack and workload confound the first account, and neither product was verified. forumanecdote
- Weeks 1–2: Slight better session tolerance or cardio ease is the common positive checkpoint — not big strength jumps or dramatic scale drops alone. forum
- Weeks 3–4: Frequent decision point: keep for cut/endurance story, drop for sides (sleep), or question product/absorption if zero change. forum
- Weeks 6–8: Typical full community “cycle” end; results almost always framed as training + diet ± stack, not drug-alone. forum
- Weeks 8–10: Some extend toward ~10 weeks in cut prep talk; longer continuous human safety still uncharacterized. forum
- No change by ~3–4 weeks: Forums first blame once-daily dosing, underdose, fake/underdosed liquid, or oral bioavailability — not automatic mega-dose. forum
- Post-cycle: Subjective energy/conditioning often fades; residual fitness may stick from actual cardio volume. anecdote
Cycles people discuss
- Typical on-length: ~6–8 weeks is the most repeated community cycle window. forum
- Shorter trial: ~4 weeks to gauge feel, sleep impact, and whether any cardio/recomp story appears before committing longer. forum
- Extended talk: Some logs stretch toward ~8–10 weeks around contest/cut blocks; still not a standardized safety schedule. forum
- Time off: Often roughly match on-time (e.g. 6–8 weeks off); practices vary and are not pharmacology-derived. forum
- No classic PCT narrative: Forums generally say SR9009 alone does not require AAS-style PCT because it is not an AR agonist — stack partners may still need their own recovery plans. forum
- Stacked cycles: Rarely run pure solo in serious cut logs; usually with Cardarine, deficit, mild SARM (especially Ostarine), and/or MK-677 “functional” stacks. forum
- Re-runs: Common across cut seasons or race blocks; multi-season human safety database does not exist. forum
- Continuous open-ended use: Discussed by people treating it like a “metabolic daily,” but long-term circadian/cardiac unknowns push most guides back to cycled blocks. forumtrial
Timing
- Human oral half-life: Not established. Forum posts repeat roughly four-hour estimates, but the inspected primary program is cell and mouse research and does not provide a clinical oral elimination value. forumtrial
- Why split doses: Short circulating duration → 3–4× daily oral to keep “coverage,” vs Cardarine’s once-daily ~12–24 h community half-life culture. forum
- Practical sleep timing is disputed: In one discussion, an author taking three daily doses about four hours apart, including at night, reported strong sleep amid heavy workload and a GW-501516 stack; a liquid user reported reduced deep sleep. No controlled human timing comparison establishes a cutoff. forumanecdote
- Adaptations vs blood levels: Users claim conditioning or fat-loss trajectory can outlast each individual dose window (training + gene-program story); not a measured human “effect half-life.” anecdote
- Pre-cardio timing: Optional dose 30–45 min pre-session for perceived performance bump during long cardio. forum
- Washout: Subjective effects fade with last doses + training; formal human washout PK not published. forum
- Published animal PK paraphrases: Secondary and paper discussions also reference short clearance (e.g. ~2 hour half-life language in some cardiac-model write-ups) — exact value depends on species, route, and matrix; human oral t½ is not established. animaltrial
- PK source honesty: Published exposure work is animal-route (IP dominant); consumer oral Cmax/AUC charts are not clinical PK. animal
- WADA detection: Prohibited as hormone/metabolic modulator; anti-doping literature includes metabolic profiling of SR9009 (and SR9011) for urine LC-MS detection — timing games for tested athletes are moot. trial
More on what it is
- Not a SARM: Does not bind androgen receptors. Fitness shops and “SARM stack” SKUs often mislabel it as a SARM; pharmacology is REV-ERB / circadian–metabolic, not androgen-selective modulation. trialforum
- Route gap (core honesty): Landmark mouse efficacy used intraperitoneal (IP) injection at high mg/kg; consumer talk is almost all oral capsules/liquids. Oral bioavailability in rodents is widely summarized as very poor (~2% in secondary write-ups of Solt et al. 2012). animalforum
- What it is not: Not pharmacy medicine, not a training substitute, not “clean clock drug” only (off-target cell effects documented), not interchangeable with GW-501516/PPARδ or SLU-PP ERR agonists. trialforum
- What it is: Synthetic small-molecule agonist of nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2); gray-market nickname Stenabolic. Developed in the Thomas Burris / Scripps Research line (with earlier GSK4112 as a structural ancestor). Not a peptide. trial
- Binding (published): Literature cites IC50 roughly ~670 nM (REV-ERBα) and ~800 nM (REV-ERBβ) for the constitutive repression assay context used to characterize the ligand. trial
- Why people care: 2012–2013 mouse work (lipid/weight + ~50% treadmill running capacity) plus media “exercise in a bottle” framing → mid-tier endurance/fat-loss forum culture alongside Cardarine. animalforum
- Evidence bar: Preclinical animal/cell package is real and citable; no solid completed human RCTs or published human PK for athletic oral use as of research review windows through 2025. trial
Stacks
- Cardarine (GW-501516) + SR9009: The top named endurance/conditioning dual stack — GW for session fat-ox / longer coverage, SR for split-dose metabolic/clock narrative. forum
- Cut SARM stacks: Deficit + Ostarine (MK-2866) ± SR9009 (and often Cardarine) for recomp/cut talk; LGD-4033 or RAD-140 sometimes appear in more aggressive cut/recomp stacks — multiplies unknown risks. forum
- SOCOM / “functional” naming: Vendor and gym culture often groups MK-677 + Cardarine + SR9009 as a sleep/hunger + endurance + metabolic trio (names vary; ratios/vendor bottles vary). forum
- MK-677 adjacency: Paired when people want recovery/appetite/sleep architecture alongside conditioning agents — hunger can fight fat-loss goals. forum
- Stim / fat-burner adjacency: Caffeine or commercial fat-burners muddy energy attribution and HR feel. forum
- Peptide recovery add-ons: Some cut stacks add BPC-157/TB-500-class recovery talk while running SR for conditioning — different pathways, confounded logs. forum
- Training non-negotiable: Zone-2 volume, steps, and progressive cardio are repeatedly credited when logs look good; sedentary “pill only” stories are thin. forum
- Vs SR9011: Sibling Burris-line REV-ERB agonist; less retail volume; often described as related/shorter-acting cousin rather than a true upgrade. forumtrial
- Vs SLU-PP-332 / ERR class: Different receptor family (ERR pan-agonists vs REV-ERB); both sold as exercise-mimetic research chems — do not treat as dose-equivalent. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- No human safety package: Oral fitness use lacks adequate Phase 1 PK, MTD, or long-term controlled safety databases; absence of reports ≠ proof of safety. trialforum
- Sleep / circadian disruption: Insomnia, lighter sleep, or “wired” evenings — most discussed side; mechanistically plausible because REV-ERB regulates clock genes (e.g. BMAL1 pathway adjacency). Last-dose timing is the usual mitigation talk. forumanimal
- Week-one fatigue / lethargy: Minority report initial sluggishness before any positive feel — hard to separate from deficit and sleep debt. anecdote
- Headache / nonspecific: Occasional headache, dizziness, or “off” feel in logs; stacks and under-eating confound. forum
- GI upset: Occasional with oral liquids, solvents, or higher split totals. forum
- Testosterone narrative: Not an AR ligand; community “no suppression” claim is mechanism-based, not a large human endocrine trial. Gray-market contamination with actual SARMs can create unexpected HPTA effects; theoretical Leydig/REV-ERB interactions are discussed but not human-settled. forumtrial
- Liver: No well-characterized human DILI signal specific to verified SR9009 monotherapy; also no clearance — baseline/follow-up LFTs are common medical-hygiene talk when people disclose research-chem use. forumtrial
- Source / purity risk: Mislabeling, underdosing, wrong solvent, and substitution common; third-party assay culture is uneven. forum
- Long-term unknown: Multi-month or multi-year consumer oral use has no controlled safety ledger; circadian, metabolic, and proliferative off-target questions remain open. forumtrial
- Stack risk multiplication: Pairing with Cardarine (rodent carcinogenicity history for GW), suppressive SARMs, or high-stim cut agents stacks unknowns without adding human SR9009 safety data. forumanimal
- Sparse-honesty bottom line: Best evidence is high-dose IP mouse metabolism/endurance; human oral “20–30 mg split” culture is folklore reverse-engineered around a short half-life and a poor-oral-F molecule. trialforum
- Off-target / REV-ERB-independent effects (cells): Dierickx et al. PNAS 2019 — SR9009 decreased cell viability, rewired metabolism, and altered transcription even in cells lacking both REV-ERBα and REV-ERBβ; effects cannot be attributed solely to on-target REV-ERB agonism. labtrial
- Cardiac / circadian theoretical cautions: Preclinical literature ties REV-ERB biology to heart remodeling, inflammation, and sleep/wake — short rodent IP studies are not multi-year human cardiac clearance. Some models explore SR9009 in pressure-overload heart contexts (research, not consumer proof of safety or benefit). animal
- Legal / regulatory: Not an approved drug for endurance or fat loss; sale for human consumption is restricted under food/drug frameworks in many jurisdictions even when not a scheduled narcotic. trial
- WADA / sport: Prohibited (Hormone and Metabolic Modulators / related S4 framing in anti-doping materials); bodybuilding abuse reports helped drive listing; positives are treatable as serious anti-doping violations. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.